Global 3D Bioprinting Market 2017-2021
About 3D Bioprinting
A 3D bioprinter is a mechanical device that can print three-dimensional biological structures such as tissue or organs. The materials used in the bioprinting process are specifically engineered and infused with living cells (except for metals and ceramics). The ancillary equipment comprises primarily of tools and devices used to cultivate the bioprinted structure.
Technavio’s analysts forecast the global 3D bioprinting market to grow at a CAGR of 25.06% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global 3D bioprinting market for 2017-2021. To calculate the market size, the report considers the revenue generated by the vendors by sales of 3D bioprinters, materials used in the bioprinting process, as well as the services and ancillary equipment that are used post the bioprinting process.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global 3D Bioprinting Market 2017-2021
Technavio recognizes the following companies as the key players in the global 3D bioprinting market: 3D Bioprinting Solutions, 3D Biotek, Advanced BioMatrix, BioBots, CELLINK, Cyfuse Biomedical K.K., Digilab, EnvisionTEC, InSphero, Organovo, and SHINING 3D TECH.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is collaboration among the end-users for knowledge sharing purposes. The current end-users of 3D bioprinters are mostly limited to research organizations, bioengineering laboratories, and universities. In April 2016, the Italian Regenerative Medicine Infrastructure (IRMI) has initiated the setting up of advanced infrastructure in the European region to ensure sharing of knowledge and 3D bioprinting technologies among different disciplines in the genre of regenerative medicine. The IRMI is organized and facilitated by nine Italian universities, five research organizations, and seven private societies.”
According to the report, one of the major drivers for this market is companies providing low-cost 3d bioprinters penetrating the market. 3D bioprinters are complex and much more advanced than traditional 3D printers. These complexities make the 3D bioprinter expensive to procure. However, the prices of the 3D bioprinters are witnessing a steep decline mainly due to the increasing number of new vendors entering the market. These vendors are providing low-cost 3D bioprinters to low-budget research organizations, laboratories, and universities. Ourobotics that is a startup is selling its 3D bioprinter called Revolution, which uses syringe-based extrusion technology, at the retail price of $14,000.
Further, the report states that one of the major factors hindering the growth of this market is inability of researchers to combine vascular supply in printed tissues and organs. Although the 3D bioprinting market has witnessed major breakthroughs over the years, it is far from bioprinting a fully functional organ or tissue for transplant. The researchers are successful in bioprinting parts of an organ or tissue that has cells fully capable of performing their dedicated functions. However, they haven't been able to combine vascular veins in the printed organs, though it can be printed separately.
3D Bioprinting Solutions, 3D Biotek, Advanced BioMatrix, BioBots, CELLINK, Cyfuse Biomedical K.K., Digilab, EnvisionTEC, InSphero, Organovo, and SHINING 3D TECH.